dal 2001 al 2006 Ospedale L. Sacco, Milano Unità di Reumatologia Medico Specilaista in Reumatologia 2001 ASL 2 Olbia - Sardegna Medico-di guardia

F

A

F

E

• Date (da – a) dal 2017-2018

• Nome e indirizzo del datore di lavoro Università di Messina

• Tipo di azienda o settore Unità di Reumatologia, Dipartimento di Medicina Clinica e Sperimentale

• Tipo di impiego Professore Associato e Responsabile Unità di Reumatologia

• Principali mansioni e responsabilità

dal 2007 al 2017

Università di Milano, Ospedale L. Sacco Unità di Reumatologia

Responsabile ricerca clinica e Consultant dal 2001 al 2006

Ospedale L. Sacco, Milano Unità di Reumatologia

Medico Specilaista in Reumatologia 2001

ASL 2

Olbia - Sardegna Medico-di guardia 2001

ASL 6

San Gavino - Sardegna Medico di guardia 1995

ASL 2

Olbia -. Sardegna Medico-di guardia

I

• Date (da – a) 1995

• Nome e tipo di istituto di istruzione o

formazione Università di Cagliari Laurea in Medicina

• Principali materie / abilità

professionali oggetto dello studio Votazione: 109/110

• Qualifica conseguita

• Livello nella classificazione nazionale (se pertinente)

2000

Università di Cagliari

Specilaizzazione in Reumatologia Votazione: 50/50 cum laude

2003

Università Autonoma di Barcellona - Spagna

Specilizzazione superiore e Master in Experimental Immunology Votazione: Excellent

2005

Università di Barcellona - Spagna PhD in Experimental Immunology Votazione: Excellent cum laude 2006

Università di Barcellona - Spagna European Research MD (ricercatore) Formazione post-laurea e borse di studio

Novembre 2010 - Dicembre 2011

Senior Lecturer - Professore Associato (part-time 17,5 ore a settimana) a Queen Mary University of London (UK)

Novembre 2009 - Novembre 2010 (Borsa di studio, Italia) VisitingConsultant and research fellow in Leeds (UK) Marzo 2006 - Marzo 2007 (Borsa di studio Eular)

Post-dottorato in Immuno-neuroendocrinologia, Università di Regensburg, Unità di Immunologia, Germania (EULAR grant)

2005

Fellowship- PhD student, Ospedale specializzato in

Ortopedia e Reumatologia, Cornell University, New York, USA (6 mesi) 2001-2005

PhD student in Experimental Immunology (Borsa di studio, Spagna) Universita’ di Barcellona, Spagna

1999

Fellowship in Malattie autoimmuni, (Erausmus Program).

Universita’ di Barcellona, Spagna

Pubblicazioni

1. M. Benucci, M. Manfredi, G. Saviola, P. Sarzi-Puttini, F. Atzeni. Changes in atherosclerosis markers during

tocilizumab treatment in Rheumatoid Arthritis: preliminary results. Clin Exp Rheum 2012 in press

2. Mader R, Buskila D, Verlaan JJ, Atzeni F, Olivieri I, Pappone N, Di Girolamo C, Sarzi-Puttini P. Developing new classification criteria for diffuse idiopathic skeletal hyperostosis: back to square one. Rheumatology (Oxford). 2012 .

3. Turiel M, Gianturco L, Ricci C, Sarzi-Puttini P, Tomasoni L, De Gennaro Colonna V, Ferrario P, Epis O, Atzeni F. Silent cardiovascular involvement in patients with diffuse scleroderma: A controlled cross-sectional study. Arthritis Care Res (Hoboken). 2012 [Epub ahead of print].

4. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012

5. Defendenti C, Grosso S, Atzeni F, Croce A, Senesi O, Saibeni S, Bollani S, Almasio PL, Bruno S, Sarzi-Puttini P. Unusual B cell morphology in inflammatory bowel disease. Pathol Res Pract. 2012 ;208(7):387-91

6. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi Puttini P, Atzeni F.

Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. Open Rheumatol J. 2012;6:33-7.

7. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, Favalli EG, Erre G, Gorla R, Galeazzi M, Foti R, Cantini F, Salvarani C, Olivieri I, Lapadula G, Ferraccioli G; for the Gruppo Italiano di Studio sulle Early Arthritis (GISEA). Obesity reduces the response rate to anti TNF in rheumatoid arthritis. an approach to a personalized medicine. Arthritis Care Res (Hoboken). 2012.

8. Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, Podestà E, Atzeni F, Mannocci A, Biasi D, Manfredi M, Sarzi-Puttini P, Laganà B, Montecucco C. Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.

PLoS One. 2012;7(7).

9. Atzeni F, Boiardi L, Casali B, Farnetti E, Nicoli D, Sarzi-Puttini P, Pipitone N, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C.CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. Rheumatology (Oxford). 2012.

10. Di Franco M, Iannuccelli C, Bazzichi L, Atzeni F, Consensi A, Salaffi F, Pietropaolo M, Alessandri C, Basili S, Olivieri M, Bombardieri S, Valesini G, Sarzi-Puttini P.

Misdiagnosis in fibromyalgia: a multicentre study. Clin Exp Rheumatol. 2011;29(6 Suppl 69):S104-

11. Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G;

Gruppo Italiano di Studio sulle Early Arthritides (GISEA).

12. The TTTT BLyS promoter haplotype associates with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to TNF blockers.Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. Arthritis Rheum. 2012 Sep 22.

13. C Defendenti, S Grosso, A Croce, O Senesi, S Saibeni, S Bollani, PL Almasio, S Bruno, P Sarzi-Puttini, F Atzeni. B lymphocyte intestinal homing in inflammatory bowel disease. BMC Immunology 2011 [in press] IF 3.00

14. Marchesoni A, Atzeni F, A. Spadaro, E.Lubrano, G. Provenzano, A.Cauli, et al.

Identification of the clinical features distinguishing psoriatic arthritis and Fibromyalgia J of Rheumatology 2011 [in press] IF .3.857

15. Batticciotto A, Atzeni F, Foglia S, Antivalle M, Serafin A, Sarzi-Puttini P. Feet naifold is not useful to detect the typical scleroderma pattern. Clin Exp Rheum 2011 in press IF 2.4

16. Sarzi-Puttini P, Atzeni F, Mease P. Chronic widespread pain or fibromyalgia? That is the question. Best Pract Res Clin Rheumatol. 2011 25(2):131-2. IF3.486 17. Atzeni F, Boiardi L, Nicoli D, Farnetti E, Casali B, Sarzi-Puttini P, Pipitone N,

Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C. PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S38-43. IF 2.4

18. Atzeni F, Sarzi-Puttini P, Sitia S, Tomasoni L, Gianturco L, Battellino M, Boccassini L, De Gennaro Colonna V, Marchesoni A, Turiel M. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol. 2011 ;38(8):1661-4.

IF 3.85

19. Sitia S, Tomasoni L, Cicala S, Atzeni F, Ricci C, Gaeta M, Sarzi-Puttini P, Turiel M.

Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography. Int J Cardiol. 2011 Mar 28. [Epub ahead of print] IF 4.004

20. Benucci M, Saviola G, Baiardi P, Manfredi M, Sarzi-Puttini P, Atzeni F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol. 2011;24(1):269-74. IF2.685

21. Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A, Cimmino M, Fabro C, Pontarini E, Pellerito R, Bambara LM, Sarzi-Puttini P, Cutolo M, Manfredi M, Benucci M, Morassi P, Fischetti F, Padovan M, Govoni M, Curcio F, Tonutti E, De Vita S. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.. Autoimmun Rev. 2010.

[Epub ahead of print] IF 6,368

22. Defendenti C, Atzeni F, Spina MF, Grosso S, Cereda A, Guercilena G, Bollani S, Saibene S, Puttini PS. Clinical and laboratory aspects of Ro/SSA-52

autoantibodies. Autoimmun Rev. 2011 ;10:150-4. IF 6,368

23. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, de Ramon Garrido E, Gilboe IM, Tektonidou M, Blockmans D, Ravelingien I, le Guern V, Depresseux G, Guillevin L, Cervera R; the MAINTAIN Nephritis Trial Group . The members of the MAINTAIN Nephritis and the coauthors: Abramowicz D, Atzeni F, Danieli MG, De Clercq,L; de Keyser F, Delahousse M, Espinosa G, Golstein M, Hirsch M, Karras A, Lang F, Marchal M,; Marinho A, Max R, Peeters P, Petera, P; Quémeneur; Raeman F, Sarzi-Puttini, P, Valiente de Santis L, Verresen L, Weiss L, Westhovens R, Azathioprine versus mycophenolate mofetil for long- term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2011 [Epub ahead of print] IF 8,11

24. Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis. 2011. [Epub ahead of print] IF 8,11

25. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54. PubMed PMID: 20535784. IF 7,332

26. Defendenti C, Spina MF, Grosso S, Longo M, Bollani S, Cereda A, Saibeni S, Guercilena G, Atzeni F, Sarzi-Puttini P. [Frequency and clinical associations of antineutrophil cytoplasmic antibodies. A regional experience]. Recenti Prog Med.

2010 Jan;101(1):16-26. Italian. PubMed PMID: 20391682.

27. Turiel M, Tomasoni L, Sitia S, Cicala S, Gianturco L, Ricci C, Atzeni F, De Gennaro Colonna V, Longhi M, Sarzi-Puttini P. Effects of Long-Term Disease- Modifying Antirheumatic Drugs on Endothelial Function in Patients with Early Rheumatoid Arthritis. Cardiovasc Ther. 2010 Mar 10. [Epub ahead of print]

PubMed PMID: 20337633.IF 2,741

28. Boiardi L, Atzeni F, Casali B, Farnetti E, Nicoli D, Pipitone N, Catanoso MG, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C. Toll-like receptor 4 (TLR4) gene polymorphisms in Italian patients with Behçet's disease. Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S43-7. IF 2,396 29. Ghinoi A, Boiardi L, Atzeni F, Casali B, Farnetti E, Nicoli D, Pipitone N, Olivieri I,

Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C.

Protein Z G79A and A-13G gene polymorphisms in Italian patients with Behçet's disease. Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S23-8. IF 2,39 30. Salaffi F, Sarzi-Puttini P, Girolimetti R, Atzeni F, Gasparini S, Grassi W. Health-

related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. Clin Exp Rheumatol. 2009 Sep-Oct;27(5 Suppl 56):S67-74. PubMed PMID:

20074443.IF 2,396

31. Caporali R, Sarzi-Puttini P, Atzeni F, Gorla R, Filippini M, Marchesoni A, Favalli EG, Bobbio-Pallavicini F, Montecucco C. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev.

2010 Apr;9(6):465-9. Epub 2009 Dec 31. PubMed PMID: 20044040.IF 6,368 32. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M,

Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009 Dec;48(12):1557-9. Epub 2009 IF 4,236

33. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009 Sep;1173:837-46. PubMed PMID: 19758236.IF 2,303

34. Salaffi F, Sarzi-Puttini P, Girolimetti R, Gasparini S, Atzeni F, Grassi W.

Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect.

Arthritis Res Ther. 2009;11(4):R125. Epub 2009 Aug 18. PubMed PMID:

19686606; PubMed Central PMCID: PMC2745809.IF 4,271

35. Atzeni F, Sarzi-Puttini P, Vena GA. Resistant cases of psoriatic arthritis: how to manage them. J Rheumatol Suppl. 2009 Aug;83:73-5. PubMed PMID: 19661549.

IF 3.854

36. Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev. 2010 Jan;9(3):175-80. Epub 2009 Jul 30. PubMed PMID: 19647103.IF 6,368 37. Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P,

Pallavicini FB, Caporali R, Gorla R. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):90-6. PubMed PMID: 19548124. IF 2,597 38. Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, Sarzi-Puttini P.

Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J Gastroenterol. 2009 May 28;15(20):2469-71. PubMed PMID:

19468996; PubMed Central PMCID: PMC2686904. IF 2,092

39. Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD, Longhi M, Sitia S, Bianchi M, Ferrario P, Doria A, De Gennaro Colonna V, Sarzi-Puttini P. Non- invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford). 2009 Jul;48(7):834-9. Epub 2009 May 22. PubMed PMID: 19465588.IF 4,236 40. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG,

Marchesoni A, Sarzi-Puttini P. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009 Mar;8(5):431-7. Epub 2009 Jan 27. PubMed PMID: 19211043.IF 6,36

41. Sarzi-Puttini P, Antivalle M, Marchesoni A, Favalli EG, Gorla R, Filippini M, Caporali R, Bobbio-Pallavicini F, Montecucco C, Atzeni F. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN).

Reumatismo. 2008 Oct-Dec;60(4):290-5. PubMed PMID: 19132154

42. Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Gorla R. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev. 2009 Jan;8(3):260-5. Epub 2008 Nov 21. PubMed PMID: 19027090.IF 6,368

43. Favalli EG, Desiati F, Atzeni F, Sarzi-Puttini P, Caporali R, Pallavicini FB, Gorla R, Filippini M, Marchesoni A. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009 Jan;8(3):266-73. Epub 2008

Nov 18. PubMed PMID: 19022409.IF 6,368

44. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, Caporali R. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther. 2008;10(3):R51.

Epub 2008 May 7. PubMed PMID: 18462485; PubMed Central PMCID:

PMC2483440.IF 4,271

45. Straub RH, Pongratz G, Cutolo M, Wijbrandts CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich J, Lorenz HM, Tak PP, Sarzi-Puttini P.

Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Rheum.

2008 Apr;58(4):976-84. PubMed PMID: 18383357.IF 7,332

46. Atzeni F, Sarzi-Puttini P, DePortu S, Cutolo M, Carrabba M, Straub RH. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. Clin Exp Rheumatol. 2008 Jan-Feb;26(1):103-8. PubMed PMID: 18328154. IF 2,396 47. Atzeni F, Doria A, Ghirardello A, Turiel M, Batticciotto A, Carrabba M, Sarzi-Puttini

P. Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis:

prevalence and clinical value. Autoimmunity. 2008 Feb;41(1):111-5. PubMed PMID: 18176873.IF 2,813

48. Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P. Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity. 2008 Feb;41(1):87- 91. PubMed PMID: 18176869.IF 2,813

49. Sarzi-Puttini P, Atzeni F, Di Franco M, Lama N, Batticciotto A, Iannuccelli C, Dell'Acqua D, de Portu S, Riccieri V, Carrabba M, Buskila D, Doria A, Valesini G.

Anti-polymer antibodies are correlated with pain and fatigue severity in patients with fibromyalgia syndrome. Autoimmunity. 2008 Feb;41(1):74-9. PubMed PMID:

18176867.IF 2,81

50. Atzeni F, Sarzi-Puttini P, De Blasio G, Delfino L, Tomasoni L, Turiel M. Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. Ann N Y Acad Sci. 2007 Jun;1108:392-7. PubMed PMID: 17894002.IF 2,303

51. Atzeni F, Boiardi L, Casali B, Farnetti E, Sarzi-Puttini P, Pipitone N, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Filippini D, Paolazzi G, Salvarani C. Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients. Rheumatology (Oxford). 2007

Oct;46(10):1547-50. Epub 2007 Sep 12. PubMed PMID: 17855424.IF 4,236 52. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, Atzeni F,

Piccoli A, Todesco S. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006 Aug;119(8):700-6. PubMed PMID: 16887417. IF 4,446

53. Marchesoni A, Sarzi Puttini P, Gorla R, Caporali R, Arnoldi C, Atzeni F, Vianelli M, Pallavicini FB. Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):916-7. PubMed PMID: 16396721.IF 2,396

54. Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther. 2006;8(1):R3. PubMed PMID:

16356192; PubMed Central PMCID: PMC1526573.IF 4,271

55. Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, Porta A, Pace F, Malliani A, Sarzi-Puttini P. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol.

2005 Sep;32(9):1787-93. PubMed PMID: 16142879.IF 3.854

56. Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther. 2005 Sep 1;22(5):453-61. PubMed PMID: 16128684. IF 4,537

57. Turiel M, Sarzi-Puttini P, Peretti R, Bonizzato S, Muzzupappa S, Atzeni F, Rossi E, Doria A. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol. 2005 Aug 15;96(4):574-9.

PubMed PMID: 16098314. IF 3,575

58. Sarzi-Puttini P, Atzeni F, Schölmerich J, Cutolo M, Straub RH. Anti-TNF antibody

treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. Ann Rheum Dis. 2006 Mar;65(3):301-5. Epub 2005 Aug 3. PubMed PMID: 16079165;

PubMed Central PMCID: PMC1798065.IF 8,111

59. Straub RH, Härle P, Atzeni F, Weidler C, Cutolo M, Sarzi-Puttini P. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol. 2005 Jul;32(7):1253-8.

PubMed PMID: 15996060.IF 3.854

60. Turiel M, Sarzi-Puttini P, Peretti R, Rossi E, Atzeni F, Parsons W, Doria A.

Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke. 2005 Jul;36(7):1490-4. Epub 2005 Jun 9. PubMed PMID: 15947270.

IF 7,041

61. Härle P, Straub RH, Wiest R, Mayer A, Schölmerich J, Atzeni F, Carrabba M, Cutolo M, Sarzi-Puttini P. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann Rheum Dis. 2006 Jan;65(1):51- 6. Epub 2005 Jun 7. PubMed PMID: 15941834; PubMed Central PMCID:

PMC1797997.IF 8,111

62. Capsoni F, Minonzio F, Sarzi-Puttini P, Atzeni F, Ambrosi B. Thyroid acropachy:

an unusual rheumatic manifestation of Graves' disease. Clin Exp Rheumatol. 2005 Jan-Feb;23(1):125-6. PubMed PMID: 15789906.IF 2,396

63. Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M.

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.

Arthritis Res Ther. 2005;7(2):R250-5. Epub 2005 Jan 10. PubMed PMID:

15743471; PubMed Central PMCID: PMC1065317. IF 4,271

64. Straub RH, Sarzi-Puttini P, Atzeni F, Buttgereit F, Carrabba M, Cutolo M. Anti- tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases

androstenedione relative to cortisol. Ann Rheum Dis. 2005 Sep;64(9):1353-6.

Epub 2005 Feb 11. PubMed PMID: 15708882; PubMed Central PMCID:

PMC1755630.IF 8,111

65. Rizzi M, Sarzi-Puttini P, Atzeni F, Capsoni F, Andreoli A, Pecis M, Colombo S, Carrabba M, Sergi M. Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? J Rheumatol. 2004 Jun;31(6):1193-9. PubMed PMID:

15170935.IF 3.854

66. Atzeni F, Del Papa N, Sarzi-Puttini P, Bertolazzi F, Minonzio F, Capsoni F. CD69 expression on neutrophils from patients with rheumatoid arthritis. Clin Exp Rheumatol. 2004 May-Jun;22(3):331-4. PubMed PMID: 15144128.IF 2,396

67. Sarzi-Puttini P, Atzeni F, Turiel M, Furlan R, Vulpio L, Carrabba M, Pace F. The Italian version of the Fibrofatigue Scale, a reliable tool for the evaluation of fibromyalgia symptoms. J Psychosom Res. 2004 Feb;56(2):213-6. PubMed PMID:

15016581. IF 2,908

68. Atzeni F, Sarzi-Puttini P, Capsoni F, Vulpio L, Carrabba M. Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. Clin Exp Rheumatol. 2003 Nov-Dec;21(6):759-62. Review. PubMed PMID: 14740456.IF 2,396

69. Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003 Nov;35(11):814-7. PubMed PMID: 14674674. IF 2,972 70. Sarzi-Puttini P, D'Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Chérié-Lignière

EL, Panni B, Fiorentini F, Corbelli V, Beyene NB, Mastaglio C, Severi C, Locati M, Cazzola M, Menozzi G, Monti G, Saccardo F, Alfieri G, Atzeni F. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int. 2005 Jan;25(1):15-22. Epub 2003 Oct 7.

PubMed PMID: 14530867.IF 1,493

71. Sarzi-Puttini P, Atzeni F, Fiorini T, Panni B, Randisi G, Turiel M, Carrabba M.

Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I).

Clin Exp Rheumatol. 2003 Jul-Aug;21(4):459-64. PubMed PMID: 12942697.IF 2,396

72. Atzeni F, Schena M, Ongari AM, Carrabba M, Bonara P, Minonzio F, Capsoni F.

Indution of CD69 activation molecule on himan neutrophil cells by GM-CSF, IF gamma and IF alpha. Cell Immunol. 2002 Nov;220(1):20-9.PMID: 12718936. IF 2,698

73. Sarzi-Puttini P, Fiorini T, Panni B, Turiel M, Cazzola M, Atzeni F. Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. BMC Musculoskelet Disord. 2002 Jul 19;3:18.

PubMed PMID: 12133169; PubMed Central PMCID: PMC117789. IF 1,88

C

carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

MADRELINGUA ITALIANA

ALTRE LINGUA

SPAGNOLO

• Capacità di lettura eccellente

• Capacità di scrittura eccellente

• Capacità di espressione orale eccellente

ALTRE LINGUA

INGLESE

• Capacità di lettura eccellente

• Capacità di scrittura eccellente

• Capacità di espressione orale eccellente

ALTRE LINGUA

PORTOGHESE

• Capacità di lettura eccellente

• Capacità di scrittura eccellente

• Capacità di espressione orale eccellente

ALTRE LINGUA

FRANCESCE

• Capacità di lettura scolastico

• Capacità di scrittura scolastico

• Capacità di espressione orale scolastico

C

macchinari, ecc.

Utilizzo degli applicativi di Microsof Office (Word, Excel, Power Point) e dei software per gestione photo e grafica (Adobe Photoshop, Corel Photo) e software di statistica (Sigma Stat, Sigma Plot).